Source comparison
TB-500 Help Tendon Injury: Research Peptide Comparison
TB-500 (Thymosin Beta-4) Actin upregulation, promotes cellular migration Strong. 42% increase in capillary density in equine models Shifts collagen ratio toward type I (stronger fibres) 2–5mg subcutaneously 2x/week for 4–6 weeks Best-supported peptide for tend
This comparison does not assign a generated winner or score.
- TB-500 (Thymosin Beta-4)
- Actin upregulation, promotes cellular migration
- Strong. 42% increase in capillary density in equine models
- Shifts collagen ratio toward type I (stronger fibres)
- 2–5mg subcutaneously 2x/week for 4–6 weeks
- Best-supported peptide for tendon healing with direct angiogenesis promotion
- BPC-157
- Enhances growth hormone receptor expression, VEGF upregulation
- Moderate. Promotes new blood vessel formation but less studied than TB-500
- Accelerates granulation tissue formation
- 250–500mcg daily (oral or subcutaneous)
- Strong regenerative potential but lacks large animal model validation
- GHK-Cu (Copper Peptide)
- Stimulates collagen synthesis, tissue remodelling
- Mild. Primarily anti-inflammatory rather than angiogenic
- Increases collagen and elastin production
- Topical application or 1–2mg subcutaneously daily
- Useful for skin and surface tissue but limited penetration for deep tendon injury
- TB-500 stands apart due to its actin-binding mechanism. No other peptide directly regulates cellular mobility during the repair phase. BPC-157 shows promise but lacks the equine model validation that makes TB-500 a more defensible research choice. Copper peptides work well for surface-level tissue remodelling but don't address the vascularisation bottleneck that limits tendon healing.